Litigation Details for UCB, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2016)
✉ Email this page to a colleague
UCB, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2016)
| Docket | ⤷ Sign Up | Date Filed | 2016-06-17 |
| Court | District Court, D. Delaware | Date Terminated | 2018-10-17 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Patents | RE38,551 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in UCB, Inc. v. Aurobindo Pharma Ltd.
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for UCB, Inc. v. Aurobindo Pharma Ltd. (D. Del. 2016)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-10-15 | 15 | infringe claims 9, 10, and 13 of U.S. Patent No. RE38,551 (the “’551 Patent), and on Defendants’ counterclaim…the date of expiration of the ’551 Patent inclusive of the patent term extension granted under 35 U.…invalidity of claims 9, 10, and 13 of the ’551 Patent (D.I. 323 ¶¶ 16–17 in the Preceding Action), …would infringe claims 9, 10, and 13 of the ’551 Patent. 2. Judgment is entered in favor of… invalidity of claims 9, 10, and 13 of the ’551 Patent. 3. Pursuant to 35 U.S.C. § 271(e) | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
